Factors affecting the results of analgesic therapy. Results of the Russian multicentre study of NOTE (NSAID: Open-label Trial of Efficacy)

Non-steroidal anti-inflammatory drugs (NSAIDs) are most popular medications for the treatment of pain in common musculoskeletal diseases such as osteoarthritis (OA) and non-specific low back pain (LBP). However, the factors affecting the effectiveness of these drugs have not been determined fully. Aim: to identify factors affecting the effectiveness of NSAIDs in patients with OA and LBP. Materials and methods. An observational study was conducted to evaluate the effectiveness of a 2-week course of NSAIDs in OA and LBP in real clinical practice. The study group consisted of 3604 patients with OA and LBP (60.6% women and 39.4% men, mean age 55.0±13.4 years). According to the study design, aceclofenac (Airtal) and other NSAIDs used in the ratio 1:1. The main criterion of effectiveness was the frequency of complete pain relief after 2 weeks of therapy. In addition, the decrease of pain and general health were determined on a 10-point numerical rating scale (NRS). We compared the frequency of complete pain relief in patients who had and did not have the studied factors. The value of the studied factors was determined using OR (95% CI). Results and discussion. Most patients received aceclofenac (54.9%), as well as diclofenac (2.0%), ketoprofen (1.9%), lornoxicam (2.2%), meloxicam (13.7%), naproxen (2.1%), nimesulide (5.8%), celecoxib (5.9%), ethicoxib (7.1%) and other NSAIDs (4.4%); 56.2% of patients received muscle relaxants, mainly tolperisone (74.7%), vitamin B (10.4%), and proton pump inhibitors (42.8%). Complete pain relief was achieved in 54.8% of patients. The pain decrease and general health improvement were (for NRS) 63.9±13.4% and 61.7±14.8%, respectively. The efficacy of aceclofenac was slightly higher than in the whole group: complete pain relief was in 59.9% of patients. Adverse events in aceclofenac use were observed in 2.3% of patients, other NSAIDs-from 2.4 to 14.1%. The frequency of complete pain relief was higher in men: OR 1,239 (95% CI 1.08-1.418; p=0.002), who had the first episode of pain - OR 3.341 (95% CI 2.873-3.875; p=0.000), a good" response " to NSAIDs in history - OR 1.656 (95% CI 1.385-1.980; p=0.000) and received NSAIDs in combination with muscle relaxants - OR 1.218 (95% CI 1.067-1.390; p=0.004). The effect of therapy is lower in patients 65 years and older-OR 0,378 (95% CI 0.324-0.442; p=0,000), with body mass index >30 kg/m² - OR 0.619 (95% CI 0.529-0.723; p=0.000), with severe pain (≥7 points NRS) - OR 0.662 (95% CI 0.580-0.756; p=0.002), with pain at rest, - OR 0.515 (95% CI 0.450-0,589; p=0.000), pain at night - OR 0.581 (95% CI 0.501-0.672; p=0.000) and the presence of stiffness - OR 0.501 (95% CI 0.438-0,573; p=0.000). Treatment results are significantly worse in the cases of combination of LBP and joint pain, as well as pain in the trochanter major and pes anserinus area (

Оценка эффективности и безопасности комбинации хондроитина сульфата и глюкозамина сульфата при остеоартрите коленного и тазобедренного суставов в реальной клинической практике

A combination of chondroitin and glucosamine is widely used in clinical practice as both a symptomatic and structure-modifying agent for the treatment of osteoarthritis (OA). The emergence of new drugs based on this combination substantially expands treatment options for OA therapy.Objective: to evaluate the efficacy and safety of Artroflex® that is a combination of chondroitin sulfate 400 mg and glucosamine sulfate 500 mg (CS + GS) to support joint health in patients with knee and/or hip OA.Patients and methods. When implementing an open observational research program, the results of using the CS + GS complex were assessed in 644 OA patients (74.7% women) (mean age, 58.0±14.6 years) who experienced moderate/severe pain and required to continuously take non-steroidal anti-inflammatory drugs (NSAIDs). The CS + GS complex was prescribed in a dose of 2 capsules per day for 3 months. The investigators estimated changes in pain on movement by a 0 to 10 verbal pain scale, general health (GH) by a 0–10 visual analogue scale), the Lequesne index, the need for NSAIDs, and patient satisfaction with treatment and its tolerance.Results and discussion. After 3-month therapy, there were decreases in pain intensity by 49.2±16.8%, GH scores by 45.6±18.1%, the Lequesne index from 9.0 [6.0; 13.0] to 5.0 [3.0; 9.0]; less than half (45.2%) of the patients still needed for NSAIDs. 82.2% of patients were satisfied or completely satisfied with treatment results; 89.6% reported good treatment tolerance.Adverse events (apparently associated with NSAID use) were recorded in 2.2% of cases. There were no serious complications that required CS + GS treatment discontinuation or hospitalization.Conclusion. The findings have indicated that Artroflex® used to support joint health is an effective agent that controls OA symptoms and has a good safety level.Комбинация хондроитина и глюкозамина широко применяется в клинической практике как симптоматическое и структурно-модифицирующее средство для лечения остеоартрита (ОА). Появление новых препаратов на основе данной комбинации существенно расширяет возможности терапии ОА.Цель исследования – оценка эффективности и безопасности комплекса для поддержания здоровья суставов Артрофлекс®, представляющего собой комбинацию хондроитина сульфата 400 мг и глюкозамина сульфата 500 мг (ХС + ГС), у пациентов с ОА коленного и/или тазобедренного суставов.Пациенты и методы. В ходе наблюдательной открытой исследовательской программы были оценены результаты применения комплекса ХС + ГС у 644 больных ОА (средний возраст 58,0±14,6 года, 74,7% женщины), испытывающих умеренную/выраженную боль и нуждающихся в постоянном приеме нестероидных противовоспалительных препаратов (НПВП). Комплекс ХС + ГС назначали в дозе 2 капсулы в сутки сроком на 3 мес. Оценивали динамику боли при движении (по вербальной шкале боли 0–10), общего состояния здоровья (ОСЗ, по визуальной аналоговой шкале 0–10), индекса Лекена, потребность в приеме НПВП, удовлетворенность больных лечением и переносимостью терапии.Результаты и обсуждение. Через 3 мес применения выраженность боли снизилась на 49,2±16,8%, оценка ОСЗ – на 45,6±18,1%, индекс Лекена – с 9,0 [6,0; 13,0] до 5,0 [3,0; 9,0], необходимость в приеме НПВП осталась менее чем у половины больных (45,2%). Удовлетворены или полностью удовлетворены результатами лечения были 82,2% больных, хорошую переносимость терапии отметили 89,6%. Нежелательные явления (по-видимому, связанные с приемом НПВП) зафиксированы в 2,2% случаев. Серьезных осложнений, потребовавших прерывания лечения ХС + ГС или госпитализации, не выявлено.Заключение. Согласно полученным данным, комплекс для поддержания здоровья суставов Артрофлекс® – эффективное средство для контроля симптомов ОА, обладающее хорошим уровнем безопасности

PREVALENCE OF SMOKING IN ADULT POPULATION OF IRKUTSK

Smoking is a significant risk factor of chronic noncommunicable diseases. Smoking prevalence is variable in different populations. A study of the prevalence of this risk factor allows to estimate its contribution to the development of cardiovascular pathology, to plan the necessary amount of medical care for people using tobacco, and to determine the effectiveness of prevention activities in the region. As a result of the study, smoking frequency in population of the Irkutsk region older 18 years of age or over was established as 29.5 %. The number of smokers increased with age, reaching maximum value of 38.6 % in the group 30-39 years. Male smokers made maximum in the age group 30-39 years, women - in the age group of 18-19 years. The average age of smokers was 34 years, the one of nonsmokers - 43 years. The age difference was 9 years, and it was lower in the group of men than in the group of women (5 and 11 years, respectively). The number of the smoking men were 3 times larger, than women: 50.2 % and 13.5 %, respectively. Among persons with arterial hypertension, 22.1 % were smoking with the maximum frequency of smoking in age groups from 20 to 49 years. These figures point to a considerable problem of smoking in the region

Ab initio electronic structure of thallium-based topological insulators

We analyze the crystal and electronic structures of T1-based strong topological insulators T1SbTe(2), T1SbSe(2), T1BiTe(2), and T1BiSe(2) by using first-principles calculation results. The topological nature of these materials is characterized by a single Dirac cone at the Gamma point. Aside from the latter robust surface state (SS), we find trivial SSs at (around) the Fermi level for large momenta as well as deep trivial SSs at (around) Gamma. The calculated energy cuts show an isotropic shape of the Dirac cone and a simple spin structure of the cone. The strong dependence of electronic structure on both optimization of the chalcogenide atom position in bulk and surface relaxations, as well as the slow convergence of the Dirac cone with respect to the film thickness, are discussed. The situation in the thallides is contrasted with results for isostructural indium compounds InBiTe2 and InSbTe2, the latter not being topological insulators

Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results)

Preliminary results of interregional program “Social and economic consequences of rheumatic diseases” diagnostic stage are presented.Objective. Clinical examination of persons with joint pathology revealed during screening to determine the diagnosis.Material and methods. A group of persons, who had joint complaints at the examination or during the previous year, was randomly formed according to the results of screening. Thorough uniform clinical examination with participation of a qualified rheumatologist aimed to precise determination of rheumatic pathology character was performed in all cases. During screening 1755 from 2723 persons examined at diagnostic stage positively answered question about presence of joint swelling and 968 complained of pain in knee and hip joints.Results. In 1971 from 2723 persons (72,4%) different rheumatic diseases were diagnosed. Nonrheumatic pathology was revealed in 371 (13,6%), low back pain – in 218 (8%) persons. In 163 (6%) persons no disease was determined. Osteoarthritis (49%) and rheumatoid arthritis (3%) were the most frequent causes of joint complaints. Other RD were revealed in 20%.Conclusion. Preliminary results of program diagnostic stage demonstrated significance of joint pathology problem and allowed to get the first data about structure of RD among adult inhabitants of Russia

Placental growth factor and apoptosis as early prognostic factor of placental insufficiency

Filonenko T.G., Davydova A.A., Ermola Yu.A., Nechiporenko G.V., Shalanin V.V., Syurina N.A., Menshikova O.P., Kuzmin M.N., Fedotov V.V., Beketov A.A. Placental growth factor and apoptosis as early prognostic factor of placental insufficiency. Journal of Education, Health and Sport. 2015;5(1):69-74. ISSN 2391-8306. DOI: 10.5281/zenodo.13990 http://ojs.ukw.edu.pl/index.php/johs/article/view/2015%3B5%281%29%3A69-74 https://pbn.nauka.gov.pl/works/527851 http://dx.doi.org/10.5281/zenodo.13990 Formerly Journal of Health Sciences. ISSN 1429-9623 / 2300-665X. Archives 2011 – 2014 http://journal.rsw.edu.pl/index.php/JHS/issue/archive   Deklaracja. Specyfika i zawartość merytoryczna czasopisma nie ulega zmianie. Zgodnie z informacją MNiSW z dnia 2 czerwca 2014 r., że w roku 2014 nie będzie przeprowadzana ocena czasopism naukowych; czasopismo o zmienionym tytule otrzymuje tyle samo punktów co na wykazie czasopism naukowych z dnia 31 grudnia 2014 r. The journal has had 5 points in Ministry of Science and Higher Education of Poland parametric evaluation. Part B item 1089. (31.12.2014). © The Author (s) 2015; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland and Radom University in Radom, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 15.06.2014. Revised 05.10.2014. Accepted: 25.12.2014.   PLACENTAL GROWTH FACTOR AND APOPTOSIS AS EARLY PROGNOSTIC FACTOR OF PLACENTAL INSUFFICIENCY   Filonenko T.G., Davydova A.A., Ermola Yu.A., Nechiporenko G.V., Shalanin V.V., Syurina N.A., Menshikova O.P., Kuzmin M.N., Fedotov V.V., Beketov A.A.   Departement of pathomorphology. State Institution “Crimea State Medical University named after S.I. Georgievsky”, Simferopol, Crimea Republic, Russian Federation   Summary Aim is to determine and measurement of placenta growth factor (PLGF), to demonstrate apoptosis in the human placenta in normal and abnormal pregnancies would usefully predict subsequent placental insufficiency. Clinico-functional evaluation of fetoplacental complex and definition of placental growth factor (PLGF) activity in serum of 55 pregnant women has been carried out. Histological verification of chronic placental insufficiency showed 3 types of patients: Compensatory chronic placental insufficiency, Subcompensatory and Subcompensatory with acute decompensation. Immunohistochemically a cross-sectional study was conducted to determine the expression of antybodies: marker of angiogenesis - CD34 , of apoptosis - P53 and antiapoptotic protein bcl2. Calculation of number of positive cells on 3-d visual areas of slide (200 magnification) took place. Comparing information of indexes of level of PLGF in the whey of blood, indexes of CD34 positive vessels and apoptosis it is possible to suppose that the investigated data show the dynamics of pathomorphologic changes in a placenta at chronic placenta insufficiency and can be diagnostic criteria.   Key words: human placenta, abnormal pregnancies, angiogenesis, apoptosis